Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. - Wikidata - awgldk - TriplyDB

Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis.

Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q33514600

about

Interventions for treating sexual dysfunction in patients with chronic kidney disease Maca (L. meyenii) for improving sexual function: a systematic review The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction Vasoactive intestinal polypeptide, an erectile neurotransmitter, improves erectile function more significantly in castrated rats than in normal rats Avanafil for male erectile dysfunction: a systematic review and meta-analysis.Efficacy of Continuous Dosing of Tadalafil Once Daily vs Tadalafil On Demand in Clinical Subgroups of Men With Erectile Dysfunction: A Descriptive Comparison Using the Integrated Tadalafil Databases The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.Treatment options for sexual dysfunction in patients with chronic kidney disease: a systematic review of randomized controlled trials A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials.Painful and involuntary multiple sclerosis.Efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials.Current Diagnosis and Management of Erectile Dysfunction Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities Phosphodiesterase sequence variants may predispose to prostate cancer.Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review Prescription opioids for back pain and use of medications for erectile dysfunction.Prevalence and medical management of erectile dysfunction in Asia.Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction.Clinical and molecular genetics of the phosphodiesterases (PDEs).Sexual evaluation and treatment of ageing males with haemophilia.A state of art review on vardenafil in men with erectile dysfunction and associated underlying diseases.ADMET considerations for phosphodiesterase-5 inhibitors.Efficacy and satisfaction rates of oral PDE5is in the treatment of erectile dysfunction secondary to spinal cord injury: a review of literature.Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: an empirical assessment.An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.Testosterone replacement therapy: should it be performed in erectile dysfunction?The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.2015 CUA Practice guidelines for erectile dysfunction.Taking the stress out of treating erectile dysfunction.Pituitary imaging findings in male patients with hypogonadotrophic hypogonadism.Effects of Two Different Dosages of Sildenafil on Patients With Erectile Dysfunction.Sildenafil for erectile dysfunction in the Middle East: observational analysis of patients with diabetes and/or hypertension treated in the clinical practice setting.Basics of meta-analysis: I2 is not an absolute measure of heterogeneity.Cyclic nucleotide phosphodiesterase-1C (PDE1C) drives cell proliferation, migration and invasion in glioblastoma multiforme cells in vitro.Effects of taking tadalafil 5 mg once daily on erectile function and total testosterone levels in patients with metabolic syndrome.An integrated approach with vardenafil orodispersible tablet and cognitive behavioral sex therapy for treatment of erectile dysfunction: a randomized controlled pilot study.Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study.Sildenafil increases serum testosterone levels by a direct action on the testes.

P2860

Q24235471-1739DB6A-77C0-447D-A131-112C8D61C7DA Q24626601-36EF8710-2045-4553-8EAD-59696D4A5625 Q26747680-80064B67-C687-4875-AA8F-FC43FE18013B Q26749094-F0387F29-5B3C-4359-B75A-235EC0039E5F Q28574595-E23326A6-2BF8-48AA-AA74-C806E3A831CD Q33621456-E25E19E9-7DB1-4C54-A1FF-2C6AF1342347 Q33623356-2A83C28B-FC7A-402E-B5B6-BB52A962FD3E Q33844740-8E9C8A0C-12D6-4E52-B9F5-E38BD7E583B5 Q33888333-D3AEC3D5-1D25-4E57-B2A9-4646673C6BBD Q34129318-C8FAEC3A-588B-4E0F-8975-37398AAA168C Q34364927-34EF7820-799B-41FE-8A2C-C0FC3BD93064 Q34786264-288EA031-D6E7-4CF2-B082-DFB6792ECAF7 Q35039361-E76BD486-3538-417A-9A59-C33DBC760BAF Q35384480-C9AEBFEF-02EC-49BA-8D8D-AF65106D933E Q35840149-13A725F8-D03F-428B-B0FE-A2BF6A850C13 Q35843428-51C74206-978E-4682-8DF2-D8BA054FCBDF Q36207705-272395F0-C33A-4C5F-B68D-40057D4CDD71 Q36836709-033C6AB5-4CA6-4455-A4F9-CC1726A2D611 Q37085409-BC8A2CFB-40AF-4435-A46F-D848647F6C4E Q37180996-C2E70A5C-05DD-49C2-88D0-AA81BB659EF3 Q37657841-124F25F2-0CC2-43F2-8182-722BB0530B86 Q37849338-AEBA4BA2-74D8-43B7-B515-DC03B55C1818 Q37872747-9E382CC5-6186-42CF-9288-894C15727924 Q38024409-DF0D76C5-B3AE-4784-B37A-630B6D09065F Q38038386-A6426616-32EB-4D5C-819D-0A6792460EC7 Q38091030-0FF1EBE7-BC24-4FC3-8A1C-6D80ED01E99A Q38107001-2775C03A-C969-47F4-A4AB-D9C9D48BE9B1 Q38172216-643978B2-D395-4D80-8DDD-BE7D24AF79DA Q38692296-166E615E-0E1D-4CC1-B266-6F5E84A3DE21 Q42062796-CFF4819C-00E7-4A38-A7B8-D5FB665FA565 Q42103057-11427A49-9D9F-41AA-95EA-1E2711B44E1D Q45220536-4A1DA765-4542-454B-ABAF-C06129F0750B Q45765631-E41A4F75-4005-49EB-A0D0-E3BEC71A4908 Q46794096-1E71B64F-ADD7-40C0-9F09-1C6578BBCD8E Q48020162-BAAD6F39-7F7B-4268-84A4-4C49C4058FB9 Q48360844-8A6E4F8F-A35C-42E5-B788-06C2889C864E Q48682809-6BA02104-E3AF-472B-9052-DAA75961D68D Q48955240-833859F5-C3B3-4594-9C3D-268312BB924E Q53090601-6E9B6A65-64D6-4104-B049-B90554000A8A Q55502825-4DC11201-A360-4AEF-B519-82F7911088A6

P2860

Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q33514600

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Oral phosphodiesterase-5 inhib ...... atic review and meta-analysis.

@ast

Oral phosphodiesterase-5 inhib ...... atic review and meta-analysis.

@en

Oral phosphodiesterase-5 inhib ...... atic review and meta-analysis.

@nl

type

label

Oral phosphodiesterase-5 inhib ...... atic review and meta-analysis.

@ast

Oral phosphodiesterase-5 inhib ...... atic review and meta-analysis.

@en

Oral phosphodiesterase-5 inhib ...... atic review and meta-analysis.

@nl

prefLabel

Oral phosphodiesterase-5 inhib ...... atic review and meta-analysis.

@ast

Oral phosphodiesterase-5 inhib ...... atic review and meta-analysis.

@en

Oral phosphodiesterase-5 inhib ...... atic review and meta-analysis.

@nl

P1433

Q33514600-6F07FD28-78AC-4290-B751-E4E677E171F0

P1476

Q33514600-444108B7-7BD2-45A6-B419-FB9826E069E9

P2093

Q33514600-2CADED6D-8189-401A-8CFC-5245030DDAEC

Q33514600-4F9D3A94-CF6B-4A1B-AE65-6AC57D23AD97

Q33514600-5F0890B2-089B-416C-BECB-D4D2ADB257CF

Q33514600-620C1B7F-0BFC-471B-B9D3-438C8D4AA531

Q33514600-812E43F1-9A85-4183-B6E5-6F284803BA52

Q33514600-8DD5E8D5-3E9C-4BFC-8B8A-F4067FE18BC9

Q33514600-B739BCC6-BE2E-4970-9B1C-E45CAF3DBD12

Q33514600-CCCDE3C9-6825-41E1-A72B-D1DA23B78E50

Q33514600-CEFDFD04-0A58-42B1-AA7A-7503E1095D26

Q33514600-D015A596-A276-4D9C-979E-F29131F0E53D

P304

Q33514600-45B3288E-8DCD-4081-BC4A-65AA26AF8950

P31

Q33514600-1CCF0F58-3069-42E3-B005-74D29E36845F

Q33514600-f3fd9080-ed6d-4a1d-87a8-2a4906c1950d

P356

Q33514600-5578D3BC-A8E1-41B6-92BF-DD206FF87F57

P407

Q33514600-0D1A3175-D399-4F94-977F-B280E2C1BA01

P433

Q33514600-991BB231-204F-47E7-9B6F-CB5369927196

P478

Q33514600-E6079484-21E9-40BB-9E9D-F18D218FE1E7

P50

Q33514600-39D5ECE3-DDB0-44C2-B11F-663A1EC31707

P577

Q33514600-9CB6A58E-5E2B-4F96-8CF0-FED16FF34C9C

P698

Q33514600-744E5F20-A06C-4D1F-BF30-A30052D333CC

P921

Q33514600-65A6E8E0-6FA9-4C6C-BC96-01A10EAF33A0

P356

0003-4819-151-9-200911030-00150

P1433

Annals of Internal Medicine

P1476

Oral phosphodiesterase-5 inhib ...... atic review and meta-analysis.

@en

P2093

Alexander Tsertsvadze

http://www.w3.org/2001/XMLSchema#string

Anthony J Bella

http://www.w3.org/2001/XMLSchema#string

Chantelle Garritty

http://www.w3.org/2001/XMLSchema#string

Fatemeh Yazdi

http://www.w3.org/2001/XMLSchema#string

Howard A Fink

http://www.w3.org/2001/XMLSchema#string

Karla Soares-Weiser

http://www.w3.org/2001/XMLSchema#string

Margaret Sampson

http://www.w3.org/2001/XMLSchema#string

Mohammed T Ansari

http://www.w3.org/2001/XMLSchema#string

Raymond Daniel

http://www.w3.org/2001/XMLSchema#string

Roderick MacDonald

http://www.w3.org/2001/XMLSchema#string

P304

650-661

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7326/0003-4819-151-9-200911030-00150

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

151

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19884626

http://www.w3.org/2001/XMLSchema#string

P921